Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater understanding of the aetiology of diseases, it is generally accepted that the current approach to creating new small molecule therapeutics remains fundamentally inefficient.
This article explores whether adopting a more holistic drug-hunting approach may increase effectiveness and ultimately prove more sustainable, and provides a strategic vision of what needs to happen next.
Bringing a novel therapeutic to the market is a lengthy process requiring endurance and commitment. Scientific and technological advances and greater understanding of the underlying mechanisms of disease are needed to fuel the discovery of new treatments and cures, but the overall cost of research and development are being driven higher by greater regulatory stringency and longer times to market impact discovery funding.